Self-reported loneliness associated with hearing loss risk
According to the British Academy of Audiology, hearing loss (HL) is the second most common disability in the UK, affecting …
Post
-
-
Sellas doses first paediatric subject with AML in Phase II trial of SLS009
Sellas Life Sciences has dosed the first paediatric subject with acute myeloid leukaemia (AML) in its multi-centre Phase II trial …
-
AviadoBio begins Phase I/II trial of FTD-GRN gene therapy in the UK
AviadoBio has opened the multi-centre Phase I/II ASPIRE-FTD trial in the UK, aimed at assessing the gene therapy candidate AVB-101 …
-
Nuance seeks China approval for Ohtuvayre following Phase III trial success
Nuance Pharma’s Ohtuvayre (ensifentrine) has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in …
-
Abbott’s studies show CGM technology linked to lower heart hospitalisation risk
Abbott's REFLECT real-world retrospective studies indicate that FreeStyle Libre continuous glucose monitoring (CGM) technology use is linked to a significant …
-
Are regulators keeping pace with AI adoption in clinical trials?
AI is increasingly being adopted by sponsors for various applications in clinical trials, including optimising trial design, identifying suitable patients …
-
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer
MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), with or without bevacizumab, …
-
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective inhibitor, …
-
Podcast: AI and Supervised Machine Learning in Clinical Trials – Ep1
AI and supervised machine learning have considerable benefits for clinical trials. The first episode in this GlobalData-produced series by Zelta …
-
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following the …
-
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004, …
-
Natural history research is powering more effective decision-making in oncology clinical trials
In the US alone, over 7,000 different rare diseases affect more than 30 million people[i]. Many of these conditions are …
-
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Nuvig Therapeutics has dosed the first subject in its multi-centre Phase II INVGOR trial of recombinant human immunoglobulin G1-crystallisable fragment …
-
Examining shifts in clinical trial outsourcing
As clinical trials grow increasingly complex and globalised, industry leaders continue to reassess how outsourcing models can drive efficiency and …
-
Childhood trauma and depressive predominance polarity in bipolar disorder
People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive episodes than manic …
